Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis

References

• Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: Results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis. 2012;59(1):75–83
   PubMedGoogle Scholar
• Osta V, Natoli V, Dieguez S. Evaluation of two rapid tests for the determination of microalbuminuria and the urinary albumin/creatinine ratio. An Pediatr (Barc). 2003;59(2):131–137
   PubMedGoogle Scholar
• Ting RZ, Luk AO, Chan JC. Treatment and landmark clinical trials for renoprotection. Contrib Nephrol. 2011;170:184–195
   PubMedGoogle Scholar
• KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–S154
   PubMed Web of Science ®Google Scholar
• Luk A, Chan JC. Diabetic nephropathy – What are the unmet needs? Diabetes Res Clin Pract. 2008;82 (Suppl 1):S15–S20
   PubMedGoogle Scholar
• Xiao Y, Liu Y, Yu K, et al. The effect of chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: A systematic review and meta-analysis. Evid Based Complement Alternat Med. 2013;2013:937549
   PubMed Web of Science ®Google Scholar
• Liu X, Liu L, Chen P, et al. Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy – a systematic review based on a subgroup analysis. J Ethnopharmacol. 2014;151(2):810–819
   PubMedGoogle Scholar
• Lo HC, Hsieh C, Lin FY, Hsu TH. A systematic review of the mysterious caterpillar fungus in Dong-ChongXiaCao (Dong Chong Xia Cao) and related bioactive ingredients. J Tradit Complement Med. 2013;3(1):16–32
   PubMedGoogle Scholar
• Yue K, Ye M, Zhou Z, Sun W, Lin X. The genus Cordyceps: A chemical and pharmacological review. J Pharm Pharmacol. 2013;65(4):474–493
   PubMedGoogle Scholar
• Wang Y, Yin H, Lv X, et al. Protection of chronic renal failure by a polysaccharide from Cordyceps sinensis. Fitoterapia. 2010;81(5):397–402
   PubMedGoogle Scholar
• Guo P, Kai Q, Gao J, et al. Cordycepin prevents hyperlipidemia in hamsters fed a high-fat diet via activation of AMP-activated protein kinase. J Pharmacol Sci. 2010;113:395–403
   PubMed Web of Science ®Google Scholar
• Cho HJ, Cho JY, Rhee MH, et al. Inhibitory effects of cordycepin (3'-deoxyadenosine), a component of Cordyceps militaris, on human platelet aggregation induced by thapsigargin. J Microbiol Biotechnol. 2007;17(7):1134–1138
   PubMedGoogle Scholar
• Kim HG, Shrestha B, Lim SY, et al. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-kappaB through Akt and p38 inhibition in RAW 264.7 macrophage cells. Eur J Pharmacol. 2006;545(2–3):192–199
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8(5):336–341
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition,diagnosis and classification of diabetes mellitus Report of a WHO consulation, in Geneva World Health Organization. Geneva: World Health Organization; 1999:442–443
   Google Scholar
• Mogensen CE, Chachati A, Christensen CK, et al. Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest. 1985;9(2):85–95
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12
   PubMedGoogle Scholar
• Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412
   PubMed Web of Science ®Google Scholar
• Gao TW, Wei JS. The effect of Jinshuibao Capsule in treatment of 100 patients with diabetic nephropathy. Health Must-Read. 2013;12(3):291
   Google Scholar
• Song J, Li YH, Yang XD, Guo L, Hu Z. Effect of combined therapy with bailing capsule and benazepril on urinary albumin excretion rate and c-reaction protein in patients with early diabetic nephropathy. Chin J Integr Med. 2009;29(9):791–793
   Google Scholar
• Xiong J. The effects of bailing capsule on protein marker of renal tubular in patients with diabetic nephropathy. Zhejiang Med J. 2011;33(8):1230–1231
   Google Scholar
• Zeng SX, Zhang LM. Clinical observation of Irbesartan combined with Jinshuibao Capsule in treatment of type 2 diabetic nephropathy. Chin J Postgrad Med. 2010;33(24):35–37
   Google Scholar
• Zhang YK. The effections of Irbesartan combined with Jinshuibao capsule on old patients with type 2 diabetic nephropathy. Jilin Med J. 2011;32(12):2342
   Google Scholar
• Li XL. Clinical effects of losartan combined with bailing capsule in treatment of patients with early diabetic nephropathy. J Tradit Chin Med Inform 2010;2(30):184–185
   Google Scholar
• Lou PH, Long XS, Li LB. Clinical observation of valsartan combined with bailing capsule in treatment of early diabetic nephropathy. J Pract Med. 2010;26(20):3780–3782
   Google Scholar
• Cui Y, Li JH, Chen J, et al. The nephroprotection of Angiotensin Converting Enzyme Inhibitors (ACEI) combined with Jinshuibao capsule to diabetic nephropathy patients in clinical research. J Qiqihar Med Coll. 2010;31(14):2256–2257
   Google Scholar
• Huang T, Sun H, Wu TY. Effect of combined therapy with jinshuiba capsule and perindopril on renal function in old patients with early diabetic nephropathy. Herald Med. 2010;29(7):890–892
   Google Scholar
• Li H, Nv JN. The nephroprotection of Irbesartan combined with Bailing capsule to Diabetic nephropathy with hypertension patients. China Mod Med. 2011;18(16):56–57
   Google Scholar
• Li X. Clinical observation of bailing capsule combined with valsartanl in treatment of diabetic nephropathy. China Foreign Med Treat. 2012;28:112–114
   Google Scholar
• Lin J. The nephroprotection of Valsartan combined with Jinshuibao capsule to diabetic nephropathy. Tianjin Pharm. 2009;21(6):37–39
   Google Scholar
• Liu YH, Zhao LJ, Wang LH, Gao AM. The influence of Irbesartan combined with Bailing capsule to diabetic nephropathy patients in microalbuminuria. J Chin Physician. 2011;13(2):261–263
   Google Scholar
• Qian GF, Qin JH. The clinical observation of jinshuibao capsule combined with enalapril in the treatment of diabetic nephropathy. China J Mod Drug Appl. 2012;6(10):96–97
   Google Scholar
• Shen YL, Chen K. The clinical observation of bailing capsule combined with valsartanl in treatment of diabetic nephropathy. Chin J Pract Med. 2011;38(2):124–125
   Google Scholar
• Sun QH, Wang J, Liu XL, Zhang WJ, Wang Q. Clinical effect of enalapril combined with Bailing capsule in treatment of old patients with early diabetic kidney disease. Strait Pharm J. 2012;24(10):115–117
   Google Scholar
• Wang YZ, Zhen LQ. Clinical observation of Benazepril combined with Bailing capsule in treatment of early diabetic nephropathy. J Emerg Tradit Chin Med. 2010;19(5):754–756
   Google Scholar
• Wei SJ. The clinical effects of Jinshuibao capsule combined with Benazepril in treatment of early type 2 diabetic nephropathy. Heilongjiang Med Pharm. 2010;33(1):50
   Google Scholar
• Yang JQ, Yang J. Clinical observation of Jinshuibao capsule combined with Benazepril in treatment of early diabetic nephropathy. J Chifeng Univ. 2011;3(2):100–101
   Google Scholar
• Ye JB, Liu ZM, Li JJ, Lin HZ, Lu J. Clinical observation of Bailing capsule combined with Candesartan cilexetil in treatment of early diabetic nephropathy. Intern Med China. 2012;7(6):612–613
   Google Scholar
• Yi JZ, Ding GH, Zhu L, Gao Z. The effections of Irbesartan and Jinshuibao on patients with type 2 diabetic kidney disease. J Clin Intern Med. 2009;26(11):741–743
   Google Scholar
• Yu HT, Shi HT, Xiao LL, Dong CL. The effections of Jinshuibao capsule combined with Olmesartan in treatment of early type 2 diabetic nephropathy. Contemp Med. 2013;19(23):64–65
   Google Scholar
• Hong YQ. The effections of Irbesartan combined with Bailing capsule on old patients with type 2 diabetic nephropathy. Chin J Misdiagn. 2010;10(24):5857–5858
   Google Scholar
• Li QY. Clinical observation of Irbesartan combined with Cordyceps sinensis in treatment of type 2 diabetic nephropathy. Contemp Med. 2012;18(22):82–83
   Google Scholar
• Liu Y. Clinical observation of Telmisartan combined with Jinshuibao capsule in treatment of diabetic kidney disease. China Hosp Pharm J. 2010;30(18):1573–1575
   Google Scholar
• Shan GH. The clinical observation of Bailing capsule in treatment of early diabetic nephropathy. Chin J Clin Rational Drug Use. 2012;5(11A):81–82
   Google Scholar
• Tao SC, Zhou QT. The effections of Jinshuibao capsule in treatment of early diabetic nephropathy. J Clin Res. 2009;26(7):1271–1272
   Google Scholar
• Cao LM. Clinical effects of bailing capsule combined with valsartan in treatment of patients with diabetic nephropathy. Chin J Med Guide. 2012;14(9):1571–1572
   Google Scholar
• Chen F, Chen BP, Shi J. Clinical observation of Valsartan combined with Bailing capsule in treatment of early diabetic nephropathy. China Pharmacist. 2010;13(4):551–552
   Google Scholar
• Hong RT. Observation on the treatment of diabetic nephropathy with irbesartan jointed by zhiling capsule. China Modern Doctor. 2008;46(36):96–97
   Google Scholar
• Liu CP, Li MJ. Effect of combined therapy with irbesartan and bailing capsule on urinary albumin excretion rate and C-reaction protein in patients with early diabetic nephropathy. Hebei Med J. 2011;33(13):1990–1991
   Google Scholar
• Liu XD. The clinical research of Cordyceps sinensis combined with benazepril in treatment of patients with early diabetic nephropathy. Asia Pacif Tradit Med. 2011;7(12):135–136
   Google Scholar
• Luo F, Cao S, Sun XY. Clinical research on early diabetic nephropathy treated by bailing capsule combined with Irbesartan. J Chin Med. 2011;25(4):466–467
   Google Scholar
• Lv ZM. Clinical research of zhiling capsule combined with losartan in treatment of patients with early diabetic nephropathy. Strait Pharm J. 2012;24(2):160–161
   Google Scholar
• Ma LY, Chen F, Chen BP. Effect of combined therapy with bailing capsule and irbesartan on il-8 in patients with early diabetic nephropathy. China Pharmacist. 2011;14(7):1027–1028
   Google Scholar
• Qiao AM. The effect of Telmisartan combined with Bailing capsule in treatment of 62 patients with early diabetic nephropathy. China Pract Med. 2013;8(28):177–178
   Google Scholar
• Shen SM. The clinical observation of valsartan combined with bailing capsule in treatment of 86 patients with early diabetic nephropathy. Chin J Prim Med Pharm. 2012;19(1):127–128
   Google Scholar
• Wang SY, Wu CF, Zhang H, Shi J, Chen BP. Clinical effects of bailing capsule combined with benazepril in treatment of patients with early diabetic nephropathy. China Pharmacist. 2009;12(4):501–502
   Google Scholar
• Wang YH, Yuan GF. The clinical observation of bailing capsule combined with telmisartan in treatment of patients with early diabetic nephropathy. J Clin Res. 2008;25(5):927–928
   Google Scholar
• Yan Y, Wang ZQ. Clinical observation of Bailing Capsule in treatment of patients with early diabetic nephropathy. Chin J Integr Tradit West Nephrol. 2005;6(1):46–47
   Google Scholar
• Yang XM, Yang KN, Gao W, Cao XJ. Clinical observation of Enalapril combined with Jinshuibao capsule in treatment of diabetic nephropathy. Hebei Med J. 2012;34(6):938–939
   Google Scholar
• Yu J. Clinical effects and nursing of Cordyceps sinensis combined with losartan in treatment of patients with early diabetic nephropathy. Strait Pharm J. 2012;24(7):184–185
   Google Scholar
• Zhang Y, Shi HT, Dai HS. The observation on effect of urine protein and lipid metabolism to diabetic nephropathy with Jinshuibao capsules. China Modern Doctor. 2012;50(36):64–65
   Google Scholar
• Zhen JX. Clinical observation of Irbesartan combined with Bailing capsule in treatment of type 2 diabetic nephropathy. China Mod Med. 2011;18(24):66–67
   Google Scholar
• Cao XX, Zhang RP, Yang JK. Clinical observation on treatment of diabetic nephropathy with Jinshuibao capsules and valsartan. Chin J New Drugs. 2007;16(16):1303–1306
   Google Scholar
• Lei SH, Li J, Lai XY, et al. Clinical observation of Irbesartan combined with Jinshuibao capsule in treatment of diabetic nephropathy. Shandong Med J. 2009;49(1):98–99
   Google Scholar
• Lu YL. Clinical observation of Telmisartan combined with Bailing capsule in treatment of diabetic nephropathy. Chin J Clin Rational Drug Use. 2010;3(21):43–44
   Google Scholar
• Shi HB. Clinical observation of Perindopril combined with Jinshuibao capsule in treatment of type 2 diabetic nephropathy. Chin J Pract Med. 2010;37(7):46–47
   Google Scholar
• Wang HP. Clinical observation of Fosinopril combined with Jinshuibao capsule in treatment of type 2 diabetic nephropathy. Tianjin Pharmacy. 2007;19(3):27–28
   Google Scholar
• Xue XH. Clinical observation of Irbesartan combined with Bailing capsule in treatment of type 2 diabetic nephropathy. Shanxi Med J. 2009;38(suppl):45–46
   Google Scholar
• Yang CH. Clinical observation of Jinshuibao capsule combined with losartan in treatment of early diabetic nephropathy. Mod J Integr Tradit Chin West Med. 2013;22(1):65–66
   Google Scholar
• Zhang ZF, Lv J. Clinical observation of bailing capsule in treatment of patients with early diabetic nephropathy. Shanxi Med J. 2009;38(8):730–731
   Google Scholar
• Zhou P. Clinical observation of losartan potassium with Jinshuibao capsule in patients with early type 2 diabetic nephropathy. Xinjiang Med J. 2012;42:21–23
   Google Scholar
• Chen WJ. Observation of the effect of Zhiling capsule combined with irbesartan treating early diabetic nephropathy. Mod Hospital. 2011;11(8):57–58
   Google Scholar
• Guo JZ, Yan HY. Clinical observation of irbesartan combined with Jinshuibao capsule in treatment of patients with early type 2 diabetic nephropathy. Ningxia Med J. 2012;34(9):931–932
   Google Scholar
• Liu MW. Clinical effects of losartan combined with bailing capsule in treatment of patients with diabetic nephropathy. Chin J Misdiagn. 2011;11(26):6336
   Google Scholar
• Wang L, Su XF. Effect of combined therapy with bailing capsule and losartan on microalbuminuria in patients with early type 2 diabetic nephropathy. Chin J Gerontol. 2007;27:972–973
   Google Scholar
• Wu WT. Effect analysis of valsartan and cordyceps preparation in the treatment of type 2 diabetic nephropathy. China Mod Med. 2012;19(27):71–72
   Google Scholar
• Fang YY. Clinical observation of Telmisartan combined with Jinshuibao capsule in treatment of early diabetic nephropathy. J Clin Res. 2010;27(10):1907–1908
   Google Scholar
• Guan HB, He KP, Huan WM, et al. Effect of Irbesartan with bailing capsules on microalbuminuria-to-creatinine ratio and high-sensitive C-reactive protein in patients with early diabetic nephropathy. Chin Gen Pract. 2010;13(9B):2934–2936
   Google Scholar
• Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem. 2010;17(34):4256–4269
   PubMed Web of Science ®Google Scholar
• Tang WH, Cheng WT, Kravtsov GM, et al. Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am J Physiol Cell Physiol. 2010;299(3):C643–C653
   Google Scholar
• Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes. 2008;57(2):460–469
   PubMed Web of Science ®Google Scholar
• Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012;2012:146154
   PubMed Web of Science ®Google Scholar
• Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol. 2005;289(4):F645–F659
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–340
   PubMed Web of Science ®Google Scholar
• Singh DK, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: Fueling the fire. Nat Rev Endocrinol. 2011;7(3):176–184
   PubMed Web of Science ®Google Scholar
• Liu ZY, Yao YJ, Liang ZQ, et al. Molecular evidence for the anamorph-teleomorph connection in Cordyceps sinensis. Mycol Res. 2001;105:827–832
   Web of Science ®Google Scholar
• Wang J, Liu YM, Cao W, et al. Anti-inflammation and antioxidant effect of Cordymin, a peptide purified from the medicinal mushroom Cordyceps sinensis, in middle cerebral artery occlusion-induced focal cerebral ischemia in rats. Metab Brain Dis. 2012;27(2):159–165
   PubMedGoogle Scholar
• Dworecka-Kaszak B. Cordyceps fungi as natural killers, new hopes for medicine and biological control factors. Ann Parasitol. 2014;60(3):151–158
   PubMedGoogle Scholar
• Yu HM, Wang BS, Huang SC, Duh PD. Comparison of protective effects between cultured Cordyceps militaris and natural Cordyceps sinensis against oxidative damage. J Agric Food Chem. 2006;54(8):3132–3138
   PubMedGoogle Scholar
• Xiao L, Ge Y, Sun L, et al. Cordycepin inhibits albumin-induced epithelial-mesenchymal transition of renal tubular epithelial cells by reducing reactive oxygen species production. Free Radic Res. 2012;46(2):174–183
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Wang SC. Research progress in the mechanism of Cordyceps sinensis in diabetic nephropathy. Chin J Integr Med. 2008;9(1):88–90
   Google Scholar
• Yan JK, Li L, Wang ZM, et al. Acidic degradation and enhanced antioxidant activities of exopolysaccharides from Cordyceps sinensis mycelial culture. Food Chem. 2009;117:614–616
   Google Scholar
• Choi JW, Ra KS, Kim SY, et al. Enhancement of anti-complementary and radical scavenging activities in the submerged culture of Cordyceps sinensis by addition of citrus peel. Bioresour Technol. 2010;101(15):6028–6034
   PubMedGoogle Scholar
• Rathor R, Mishra KP, Pal M, et al. Scientific validation of the Chinese caterpillar medicinal mushroom, Ophiocordyceps sinensis (Ascomycetes) from India: Immunomodulatory and antioxidant activity. Int J Med Mushrooms. 2014;16(6):541–553
   PubMedGoogle Scholar
• Dong C, Yao Y. Isolation, characterization of melanin derived from Ophiocordyceps sinensis, an entomogenous fungus endemic to the Tibetan Plateau. J Biosci Bioeng. 2012;113(4):474–479
   PubMedGoogle Scholar
• Yang L, Guo J. The influence of bailing capsule on oxidative stress in early diabetic nephropathy. Chin J Gerontol. 2012;16:3518–3520
   Google Scholar
• Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr Drug Targets. 2005;6(4): 475–486
   PubMed Web of Science ®Google Scholar
• Deng YY, Chen YP, He XL, Li L. Study of Cordyceps on mechanism in delaying chronic renal failure. Chin J Integr Tradit West Nephrol. 2001;2(7):381–383
   Google Scholar
• Hauser PV, Collino F, Bussolati B, Camussi G. Nephrin and endothelial injury. Curr Opin Nephrol Hypertens. 2009;18(1):3–8
   PubMedGoogle Scholar
• Chang QT, Fang JA. Effect of bailing capsule on the expression of nephrin in the kidney of the rats with diabetic nephropathy. Chin J Integr Med. 2010;11(1):10–13
   Google Scholar
• Ihn H. Pathogenesis of fibrosis: Role of TGF-beta and CTGF. Curr Opin Rheumatol. 2002;14(6):681–685
   PubMed Web of Science ®Google Scholar
• Gu L, Johno H, Nakajima S, et al. Blockade of Smad signaling by 3'-deoxyadenosine: A mechanism for its anti-fibrotic potential. Lab Invest. 2013;93(4):450–461
   PubMedGoogle Scholar
• Li L, He D, Yang J, Wang X. Cordycepin inhibits renal interstitial myofibroblast activation probably by inducing hepatocyte growth factor expression. J Pharmacol Sci. 2011;117(4):286–294
   PubMed Web of Science ®Google Scholar
• Fang JA, Deng GA. Experimental study on the protective effect of bailing capsule on diabetic nephropathy in rats. PhD Thesis. TongJi Medical College, HUST, Wuhan, China; 2005
   Google Scholar
• Thomson DM, Winder WW. AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol (Oxf). 2009;196(1):147–154
   PubMed Web of Science ®Google Scholar
• Kiho T, Yamane A, Hui J, Usui S, Ukai S. Polysaccharides in fungi. XXXVI. Hypoglycemic activity of a polysaccharide (CS-F30) from the cultural mycelium of Cordyceps sinensis and its effect on glucose metabolism in mouse liver. Biol Pharm Bull. 1996;19(2):294–296
   PubMedGoogle Scholar
• Yamaguchi Y, Kagota S, Nakamura K, Shinozuka K, Kunitomo M. Antioxidant activity of the extracts from fruiting bodies of cultured Cordyceps sinensis. Phytother Res. 2000;14(8):647–649
   PubMed Web of Science ®Google Scholar
• Yuan M, Tang R, Zhou Q, et al. Effect of Cordyceps sinensis on expressions of HIF-1alpha and VEGF in the kidney of rats with diabetic nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013;38(5):448–457
   PubMedGoogle Scholar
• Tu S, Zhou QL, Tang R, et al. Proapoptotic effect of angiotensin II on renal tubular epithelial cells and protective effect of Cordyceps sinensis. J Cent South Univ(Med Sci). 2012;37(1):67–72
   Google Scholar
• Shen SJ. Bailing protect against tubular injury in nephrotic syndrome. Zhejiang Med J. 2002;24(8):497–498
   Google Scholar